|
Re: Reply from Sarah
|
1
|
Zenith Epigenetics
|
Dec 11, 2015 08:18PM
|
|
Re: Reply from Sarah
|
2
|
Zenith Epigenetics
|
Dec 12, 2015 11:30AM
|
|
Re: Reply from Sarah
|
2
|
Zenith Epigenetics
|
Dec 11, 2015 02:31PM
|
|
Re: Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Feb 09, 2023 10:08AM
|
|
Re: Response & what I will attempt...
|
1
|
Zenith Epigenetics
|
Aug 17, 2020 02:13PM
|
|
Re: Response from Sarah -were still a go
|
9
|
Resverlogix Corp.
|
Dec 02, 2021 08:47PM
|
|
Re: Resverlogix and Zenith AGMs
|
1
|
Resverlogix Corp.
|
Aug 23, 2016 11:31AM
|
|
Re: Resverlogix and Zenith AGMs
|
1
|
Resverlogix Corp.
|
Aug 23, 2016 11:54AM
|
|
Re: Resverlogix and Zenith AGMs
|
1
|
Resverlogix Corp.
|
Aug 23, 2016 11:08AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
8
|
Resverlogix Corp.
|
Dec 22, 2020 01:03PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
4
|
Resverlogix Corp.
|
Apr 19, 2022 06:42PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
9
|
Resverlogix Corp.
|
Apr 19, 2022 07:14PM
|
|
Re: Resverlogix NYAS Symposium notes
|
2
|
Resverlogix Corp.
|
Apr 29, 2016 05:59PM
|
|
Re: Revamped website
|
5
|
Resverlogix Corp.
|
Jan 06, 2019 06:04PM
|
|
Re: Revamped website
|
3
|
Resverlogix Corp.
|
Jan 06, 2019 07:23PM
|
|
Re: Revamped website
|
3
|
Resverlogix Corp.
|
Jan 06, 2019 08:49PM
|
|
Re: Revamped website
|
2
|
Resverlogix Corp.
|
Jan 06, 2019 09:26PM
|
|
Re: Revamped website
|
6
|
Resverlogix Corp.
|
Jan 06, 2019 09:57PM
|
|
Re: Reverse Split, the good, bad and in between....
|
4
|
Resverlogix Corp.
|
Aug 15, 2018 02:13PM
|
|
Re: Reverse Split, the good, bad and in between....
|
2
|
Resverlogix Corp.
|
Aug 16, 2018 11:11AM
|
